Regenerate is a Phase 3 clinical trial sponsored by Intercept Pharmaceuticals for obeticholic acid (OCA) in patients with liver fibrosis due to non-alcoholic steatohepatitis (NASH). Intercept needed a brand that could establish a presence for the Regenerate study and expand to developing studies in combating conditions related to NASH. The goal was to not only create an engaging visual system for the clinical trials, but raise awareness of the growing threats of NASH.

The visual identity references the color palette of the corporate brand while adding bold, energetic colors and graphics. Recruitment materials were created to engage, educate, and empower patients to take action on their health. Assets include a patient portal, trial guides, brochures, infographics, and reference materials.